My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$URI {{ '2015-07-23T16:05:22+0000' | timeago}} • Webcast

$URI 2Q15 Call: CapEx in the quarter was $693MM and that brings the total first six months capital spend for this year to just over a $1Bil and that leaves our net rental CapEx for the second quarter & first six months at $570MM & $776MM respectively.

User Vishnu Beri {{ '2016-10-25T21:15:45+0000' | timeago}}

Apple ($AAPL) reported decline in sales and profits from comparable quarter last year, attributing the decline to announcement of iPhone 7/7s. Sales and profit are being guided higher for next quarter. Apple is a solid company and will continue to dominate tech and consumer electronics segment for a while. Personally, looks like there is little downside in this investment.

User Mark Collas {{ '2016-10-25T20:12:01+0000' | timeago}}

Waiting with fingers crossed for $AAPL’s fourth quarter earnings.

User RC xNair {{ '2016-10-25T17:04:47+0000' | timeago}}

Looking ahead to $AAPL earnings release later in the afternoon today? Gene Munster, analyst from Piper Jaffrey and the most respected authority for Apple, had this to say - "The second and slightly larger group of investors believe the tail of the iPhone 7 is irrelevant, and is betting that the iPhone 10th Anniversary will yield a jump in growth from flat to up ~15%."

User Carlton Davis {{ '2016-10-24T19:31:20+0000' | timeago}}

$COL agreed to buy $BEAV for $6.4 billion in cash and stock. Also Rockwell Collins reported higher 4Q16 earnings on growth in Government Systems and higher revenue in Information Management Services.

User Charles Elliston {{ '2016-10-24T19:15:21+0000' | timeago}}

Wow! What a buzz the $T-$TWX deal is making! Almost everyone from politicians to competitors have come out against this deal. Even Wall Street doesn’t seem to be too thrilled. Both stocks were down today.

$VRTX {{ '2016-10-25T21:17:00+0000' | timeago}} • Webcast

$VRTX stated that pricing and reimbursement approvals for patients eligible for cystic fibrosis treating drug Orkambi outside of the US are expected to drive significant revenue growth in 2017. The company expects the Orkambi launch to drive revenue growth in 4Q16 and 2017.

$JNPR {{ '2016-10-25T21:15:19+0000' | timeago}} • Announcement

$JNPR expects 4Q16 revenue of about $1.35Bil, plus or minus $30MM, and non-GAAP gross margin of about 63%, plus or minus 0.5%. $JNPR predicts non-GAAP EPS of $0.59-0.65, assuming flat share count from 3Q16. The company sees non-GAAP operating expenses of about $510MM, plus or minus $5MM, and non-GAAP tax rate about flat from 3Q.

$AKAM {{ '2016-10-25T21:12:29+0000' | timeago}} • Webcast

3Q16 revenue from $AKAM's US market was $404MM, up 1% year-over-year. The large Internet platform customers are based in the US and weighed heavily on the US market's results. Outside of these customers, revenue growth was solid across the rest of the business.

$JNPR {{ '2016-10-25T21:12:06+0000' | timeago}} • Announcement

$JNPR's BoD declared a quarterly cash dividend of $0.10 per share. The dividend is payable on Dec. 22, 2016 to shareholders of record on Dec. 1, 2016.

$AKAM {{ '2016-10-25T21:11:14+0000' | timeago}} • Webcast

Sales in $AKAM's international markets represented 31% of total revenue in 3Q16, consistent with 2Q16 and up 4 points from 3Q15. International revenue was $180MM in 3Q16, up 20% YoverY or up 17% in constant currency. ForEx fluctuations had a positive impact on revenue, $3MM on a YoverY basis and no impact on revenue on a sequential basis.